Walleye Capital
AQST icon

Walleye Capital’s Aquestive Therapeutics AQST Stock Holding History

Walleye Capital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Sell
282,568
-302,409
-52% -$1.27M ﹤0.01% 1982
2026
Q1 		$2.43M Buy
584,977
+297,166
+103% +$1.21M 0.01% 1323
2025
Q4 		$1.86M Sell
287,811
-217,463
-43% -$1.36M 0.01% 1937
2025
Q3 		$2.82M Buy
505,274
+267,370
+112% +$1.16M 0.01% 1330
2025
Q2 		$787K Buy
237,904
+198,323
+501% +$569K ﹤0.01% 2245
2025
Q1 		$115K Buy
+39,581
New +$120K ﹤0.01% 3563
2024
Q3 		– Sell
-26,892
Closed -$69.9K – 5242
2024
Q2 		$69.9K Sell
26,892
-23,543
-47% -$78.6K ﹤0.01% 4840
2024
Q1 		$215K Sell
50,435
-75,781
-60% -$252K ﹤0.01% 3933
2023
Q4 		$255K Sell
126,216
-29,372
-19% -$51.9K ﹤0.01% 3499
2023
Q3 		$238K Sell
155,588
-248,310
-61% -$427K ﹤0.01% 3418
2023
Q2 		$666K Buy
+403,898
New +$731K ﹤0.01% 2210

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Walleye Capital's AQST Position: Q2 2026 in Review

Walleye Capital reduced its Aquestive Therapeutics (AQST) stake by 52% in Q2 2026, selling an estimated $1.27M and leaving 282,568 shares worth $1.18M. The position accounts for ﹤0.01% of the portfolio, ranked #1982.

Walleye Capital first reported a position in AQST in Q2 2023 and has held it in 11 quarters since. The position peaked at $2.82M in Q3 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Walleye Capital held 282,568 shares of Aquestive Therapeutics worth $1.18M as of Q2 2026.
  • Walleye Capital sold 302,409 Aquestive Therapeutics shares in Q2 2026, an estimated $1.27M.
  • Aquestive Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #1982 holding.
  • Walleye Capital first reported a position in Aquestive Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • Walleye Capital's Aquestive Therapeutics position peaked at $2.82M in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.